Genaissance Pharmaceuticals, Inc. has entered into an agreement with INTEC Web & Genome Informatics Corporation to market all of Genaissance’s proprietary pharmacogenomics applications and products to pharmaceutical, diagnostic and biotechnology companies located in Japan.
“With INTEC W&G as our Japanese sales representative, Genaissance is expanding its potential market reach to a country that is second only to the U.S. in pharmaceutical sales,” said Kevin Rakin, President and CFO of Genaissance.
“We look forward to benefiting from INTEC W&G’s extensive network of Japanese biopharmaceutical company contacts as well as their proven track record in marketing innovative technology applications in Japan.”
Genaissance’s HAP Partnership Program offers the following benefits to biopharmaceutical companies: * Access to the HAP Database, an extensive repository of gene variation information with HAP Markers for over 5,000 pharmaceutically important genes to date.
Partners may also request genes not currently in the database.
* Licenses for individual HAP Markers for commercial applications, such as drug development, drug marketing or for diagnostic tests.
* Committed production capacity from the Genaissance sequencing facility for SNP and HAP Marker discovery, as well as the CLIA-registered HAP Typing Facility for genotyping clinical samples.
“INTEC W&G is very pleased to be working with Genaissance, the world leader in discovering gene variation information and applying it to drug development. Here in Japan, we intend to replicate the success Genaissance has achieved with U.S. and European biopharmaceutical companies,” said Munehiro Sueoka, President of INTEC W&G.
“We view the collaboration as an opportunity to expand our leadership in providing the best new technologies to our clients in Japan.”
INTEC W&G offers leading-edge technologies and advanced information systems to a wide range of customers, including corporations, universities and research institutes in the fields of bioscience and information technology.
Genaissance Pharmaceuticals, Inc. is a world leader in the discovery and use of human gene variation for the development of personalized medicines.